BIOGEN PHARMACHEM INDUSTRIES
The model puts BIOGEN PHARMACHEM INDUSTRIES at ₹0 per share — 0.0% below today's price.
Model estimate · 3 yrs of reported financials · dated 16 Nov 2026
All values are mathematically derived from financial models and do not constitute buy, sell, or hold recommendations. Models rely on historical data and assumptions that may not reflect future outcomes. StockRank is not a registered investment advisor — always do your own research before making investment decisions.
DCF model history
531752 is pricier than usual.It was this expensive or more on just 4% of days in the past 5 years.
531752 is near its most expensive valuation
Pricier than on 96% of days over 5 years
After days like today
Past results do not predict future returns.
360° view
The takeaway
A small securities-trading firm with a debt-free, equity-heavy balance sheet and recent profit growth, but very thin returns, weak long-term profit consistency and a sharp share-price decline temper the profile.
↗ Strengths
- Reported capital structure shows no borrowings and a high equity share of assets, supporting a strong accounting-capital buffer in the limited assessment.
- Latest quarterly net profit growth was strong year on year, and the three-year net profit CAGR was positive.
↘ Risks to watch
- Profitability is thin: latest ROA, ROE and ROCE were all below 1%, and profit consistency over ten years was low.
- The share price fell over the past year and remains well below its 52-week high; the trailing P/E is elevated at roughly 52x.
- Growth coverage is limited, with several revenue and earnings growth measures unavailable, so the overall ranking is not eligible.
Biogen Pharmachem Industries Limited, formerly Sun Techno Overseas Limited, is based in Rajkot, India, and engages in trading shares and securities in present and future markets. Reported revenue segments for recent fiscal years describe trading in shares and securities, with India shown as the geographic market. The company was incorporated in 1995.
Key metrics
Latest reported · price-based figures use the EOD quote5 scoring axes
How cheaply the stock is priced relative to earnings, assets, and cash flows vs peers.
60/100How cheaply the stock is priced relative to earnings, assets, and cash flows vs peers.
- Market value of equity relative to reported shareholder equity. Asset quality, profitability and accounting practices affect how the ratio should be read.
- 0.31×
- Share price relative to earnings per share over the trailing 12 months. Growth, risk and one-off earnings can affect this ratio; it is not meaningful when earnings are nonpositive.
- 52.44×
- P/E divided by the earnings-growth rate used in the ratio. Its meaning depends on that growth period and whether growth is sustainable.
- —
- Percentage difference between the saved valuation estimate and its reference share price. It depends on assumptions and is not a forecast return.
- -3.47%
Profitability, capital efficiency, and consistency of cash generation.
31/100Profitability, capital efficiency, and consistency of cash generation.
- Net profit relative to total assets. It indicates how assets generate earnings; comparisons depend on the type of business and asset quality.
- 0.86%
- Net profit relative to shareholder equity. Debt or a small equity base can raise this ratio without improving the underlying business.
- 0.86%
- The share of observed annual periods with positive common earnings within the last ten years. It describes profit frequency, not the size or stability of those profits.
- 30.00%
Revenue and earnings growth rates across multiple time horizons.
51/100Revenue and earnings growth rates across multiple time horizons.
- Earnings-per-share growth expressed as a compounded annual rate over three years. Changes in share count and one-off profits can affect the rate.
- —
- Net profit growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- 23.19%
- Net profit growth expressed as a compounded annual rate over 5 years. It smooths year-to-year changes and does not predict future growth.
- —
- Revenue change from the same quarter a year earlier. It reduces seasonal differences, but a weak comparison period can amplify growth.
- —
- Revenue growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- —
- Revenue growth expressed as a compounded annual rate over 5 years. It smooths year-to-year changes and does not predict future growth.
- —
Balance sheet strength, leverage, and financial stability.
75/100Balance sheet strength, leverage, and financial stability.
- Reported shareholder equity as a percentage of total assets. This is a limited accounting view and does not establish regulatory capital or the value of underlying investments.
- 99.69%
- Reported borrowings relative to shareholder equity. This is an accounting leverage measure and may not capture obligations within underlying investments or subsidiaries.
- 0.00×
Recent price moves and changes in earnings and institutional ownership.
38/100Recent price moves and changes in earnings and institutional ownership.
- Change in the share of equity held by domestic institutional investors over one year, in percentage points. It describes ownership changes, not the cash they invested or future returns.
- 0.00 pp
- Net profit change from the same quarter a year earlier. One-off items and a small comparison-period profit can make the percentage unusually large.
- 152.33%
- Revenue change from the same quarter a year earlier. It reduces seasonal differences, but a weak comparison period can amplify growth.
- —
- Share-price change over one year. Past price performance does not predict future returns.
- -57.35%
- Share-price change over three years in total, not per year. Past price performance does not predict future returns.
- -55.38%
Peer Companies
Other Financial ServicesQuarterly Results
₹ Cr · per share in ₹| Particulars | Dec '24 | Mar '25 | Jun '25 | Sep '25 | Dec '25 | Mar '26 | Jun '26 | Sep '26 |
|---|---|---|---|---|---|---|---|---|
| − Revenue | ||||||||
| Revenue | 0.00 | 0.00 | 1.54 | 0.00 | 0.00 | 0.00 | 0.44 | 0.00 |
| Revenue Growth YoY | — | — | 1797.25% | — | — | — | -71.26% | — |
| − Profitability | ||||||||
| Operating Profit | -0.54 | -0.17 | 1.34 | -0.39 | -0.08 | -0.94 | 0.22 | -0.03 |
| OPM % | — | — | 87.17% | — | — | — | 49.93% | — |
| Profit Before Tax | -0.31 | 1.18 | 1.34 | -0.49 | 0.46 | -0.36 | 0.22 | 0.26 |
| − Bottom Line | ||||||||
| Net Profit | -0.31 | 1.18 | 1.34 | -0.49 | 0.46 | -0.36 | 0.22 | 0.26 |
| Net Profit Growth YoY | -605.46% | 58.86% | 950.06% | 50.72% | 246.81% | -130.46% | -83.54% | 152.33% |
| EPS | -0.00 | 0.02 | 0.01 | -0.01 | 0.01 | -0.00 | 0.00 | 0.00 |
Income Statement
Annual · ₹ Cr · per share in ₹| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| − Revenue | ||||||||
| Revenue | 0.95 | 0.00 | 1.62 | 2.47 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth | — | -100.00% | — | 52.47% | -100.00% | — | — | — |
| − Expenses & Profitability | ||||||||
| Operating Profit | -0.00 | -0.12 | -1.60 | -0.02 | -0.46 | -0.45 | -1.49 | -1.60 |
| OPM % | -0.37% | — | -98.80% | -0.61% | -50.10% | -18.93% | -124.44% | -62.60% |
| Profit Before Tax | -0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 0.96 |
| − Bottom Line | ||||||||
| Net Profit | -0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 0.86 |
| Profit Growth | — | — | — | — | — | 319.57% | -115.03% | — |
| EPS | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.01 |
| Dividend / Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
Annual · ₹ CrLiabilities shown exclude shareholders’ funds and other equity. Assets equal liabilities plus equity.
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| − Equity | ||||||||
| Shareholders' Funds | 54.27 | 55.75 | 54.14 | 54.13 | 54.59 | 56.52 | 91.93 | 99.09 |
| − Liabilities | ||||||||
| Total Borrowings | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 1.14 | 0.04 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 | 0.31 |
| Total Liabilities | 3.36 | 0.35 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 | 0.31 |
| − Assets | ||||||||
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 4.65 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 | 32.78 |
| Cash & Equivalents | 0.00 | 0.00 | 0.01 | 0.08 | 0.13 | 0.02 | 2.02 | 0.32 |
| Total Current Assets | 8.04 | 8.04 | 2.56 | 1.93 | 0.15 | 0.09 | 2.67 | 0.49 |
| Total Assets | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.40 |
Cash Flow
Annual · ₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| − Cash Flows | ||||||||
| Cash from Operations | 0.09 | -1.21 | 3.95 | 1.40 | 1.70 | 1.94 | -1.08 | 1.57 |
| Cash from Investing | -0.72 | 1.54 | -3.64 | -1.32 | -1.66 | -2.06 | -32.62 | -9.56 |
| Cash from Financing | 0.62 | -0.32 | -0.31 | 0.00 | 0.00 | 0.00 | 35.70 | 6.30 |
| Net Cash Flow | -0.02 | 0.00 | 0.00 | 0.08 | 0.05 | -0.11 | 2.00 | -1.69 |
| − Cash Position | ||||||||
| Closing Cash | 0.00 | 0.00 | 0.01 | 0.08 | 0.13 | 0.02 | 2.02 | 0.32 |
Shareholding Pattern
No promoter holding is reported for BIOGEN PHARMACHEM INDUSTRIES. Public shareholders hold the most, 100.0%. The split has changed little since Sep 2023.
| Holder | Sep ’23 | Dec ’23 | Mar ’24 | Jun ’24 | Sep ’24 | Dec ’24 | Mar ’25 | Jun ’25 | 25 Jun ’25 | Sep ’25 | Dec ’25 | Mar ’26 | 18 May ’26 | Jun ’26 | Sep ’26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
Darker shading marks the quarters when that holder owned more.
Dividend History
No dividends are on record for BIOGEN PHARMACHEM INDUSTRIES.




